Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

CASIRIVIMAB\IMDEVIMAB: 4,248 Adverse Event Reports & Safety Profile

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now
4,248
Total FAERS Reports
137 (3.2%)
Deaths Reported
1,351
Hospitalizations
4,248
As Primary/Secondary Suspect
179
Life-Threatening
40
Disabilities

First Report: 19501117 · Latest Report: 20230502

What Are the Most Common CASIRIVIMAB\IMDEVIMAB Side Effects?

#1 Most Reported
Infusion related reaction
875 reports (20.6%)
#2 Most Reported
Dyspnoea
687 reports (16.2%)
#3 Most Reported
Nausea
416 reports (9.8%)

All CASIRIVIMAB\IMDEVIMAB Side Effects by Frequency

Side Effect Reports % of Total Deaths Hosp.
Infusion related reaction 875 20.6% 4 178
Dyspnoea 687 16.2% 14 322
Nausea 416 9.8% 1 115
Oxygen saturation decreased 390 9.2% 15 281
Dizziness 357 8.4% 4 66
Pyrexia 306 7.2% 4 146
Chest discomfort 294 6.9% 0 44
Chills 265 6.2% 4 107
Flushing 238 5.6% 0 16
Cough 235 5.5% 2 116
Hypoxia 222 5.2% 8 184
Incorrect dose administered 220 5.2% 2 48
Hyperhidrosis 214 5.0% 4 51
Hypotension 211 5.0% 7 79
Chest pain 208 4.9% 1 73
Vomiting 204 4.8% 3 83
Pruritus 184 4.3% 1 20
Urticaria 183 4.3% 0 26
Back pain 175 4.1% 1 25
Headache 170 4.0% 0 55

Who Reports CASIRIVIMAB\IMDEVIMAB Side Effects? Age & Gender Data

Gender: 55.4% female, 44.6% male. Average age: 54.3 years. Most reports from: US. View detailed demographics →

Is CASIRIVIMAB\IMDEVIMAB Getting Safer? Reports by Year

YearReportsDeathsHosp.
2001 2 0 1
2020 164 3 54
2021 3,567 121 1,188
2022 262 10 43
2023 4 1 0

View full timeline →

What Is CASIRIVIMAB\IMDEVIMAB Used For?

IndicationReports
Covid-19 2,943
Product used for unknown indication 256
Covid-19 treatment 208
Sars-cov-2 test positive 199
Covid-19 prophylaxis 51
Covid-19 pneumonia 38
Exposure to sars-cov-2 17
Upper respiratory tract infection 13
Post-acute covid-19 syndrome 12
Prophylaxis 9

CASIRIVIMAB\IMDEVIMAB vs Alternatives: Which Is Safer?

CASIRIVIMAB\IMDEVIMAB vs CASPOFUNGIN CASIRIVIMAB\IMDEVIMAB vs CATEQUENTINIB CASIRIVIMAB\IMDEVIMAB vs CC-4047 CASIRIVIMAB\IMDEVIMAB vs CEDAZURIDINE\DECITABINE CASIRIVIMAB\IMDEVIMAB vs CEDIRANIB CASIRIVIMAB\IMDEVIMAB vs CEFACLOR CASIRIVIMAB\IMDEVIMAB vs CEFADROXIL CASIRIVIMAB\IMDEVIMAB vs CEFAZOLIN CASIRIVIMAB\IMDEVIMAB vs CEFDINIR CASIRIVIMAB\IMDEVIMAB vs CEFEPIME

Official FDA Label for CASIRIVIMAB\IMDEVIMAB

Official prescribing information from the FDA-approved drug label.